Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

The drugs are injectable through the skin or into a vein. The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with moderate ...

Dupixent ® (dupilumab) is now used to treat over a ... with an expected U.S. Food and Drug Administration (FDA) decision by April 18, 2025, and bullous pemphigoid, for which a supplemental ...

Just to challenge a little bit of the underlying premise of the question, while we were appropriately rewarded with a broad label, the dupilumab ... The Trump administration has openly stated ...

Before we move and talk about some of the growth drivers, I'd like to just -- there's a bit of healthcare reform that has to be digested this year with the IRA, new administration. Just any ...

Linvoseltamab (BCMAxCD3) for multiple myeloma: Linvoseltamab has potential to be the best-in-class BCMAxCD3 bispecific with its differentiated clinical profile, dosing regimen and administration ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab ... has attributed to complex administration and a demanding ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory authorities with a plan for US Food and Drug Administration (FDA ... This includes Dupixent ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.